Clinical trials of a new BCG vaccine for tuberculosis begin's
Clinical trials of a new BCG vaccine for tuberculosis will soon start in India, former director-general of the Council of Scientific & Industrial Research (CSIR) Dr. Shekhar Mande said
He made these remarks at the ongoing Indian Science Congress
Earlier in the day, Dr. Mande gave a presentation on ‘Biophysical Methods in Tuberculosis Research’ and spoke about how technology has helped doctors and researchers understand TB better, paving ways to combat infectious diseases.
The CSIR is working towards rapid diagnosis, vaccination, and treatment to eliminate the bacterial disease from India by 2025 as envisioned by the government, he said, speaking to reporters later.
“We are mainly focussing on new medicines and drugs for tuberculosis.
We are doing background work and setting targets on research for prevention of tuberculosis,” he said The National Institute of Tuberculosis Research, Chennai, will start clinical trials of the new BCG vaccine for TB, he said.
Bacillus Calmette–Guérin (BCG) vaccine is primarily used against tuberculosis. According to the India TB Report 2022, the number of `incident TB patients’ (new and relapse cases) notified during 2021 stood at 19.3 lakhs.
On the government’s aim to make India TB-free by 2025, Dr. Mande said, “There is an earnest effort going across various agencies in the country. The department of health research, department of bio-technologies, and CSIR, all of them are working towards TB-free 2025.” He said that the goal is a massive challenge as the TB load in India is extremely high. “It is anticipated that about 30 percent of the population is already infected with mycobacterium tuberculosis (the bacterium that causes TB). But the good news is that about 90 percent of that 30 percent will never ever develop TB in their lifetime. And only 10 percent of those 30 percent would develop TB at some point in time.” The objective is to suppress even those 10 percent. “So, by 2025, we will actually be able to control that particular population and make India TB-free,”.

Lorem ipsum dolor sit amet, consectetur adipisicing elit. Delectus, suscipit exercitationem accusantium obcaecati quos voluptate nesciunt facilis itaque modi commodi dignissimos sequi repudiandae minus ab deleniti totam officia id incidunt? Reply
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Delectus, suscipit exercitationem accusantium obcaecati quos voluptate nesciunt facilis itaque modi commodi dignissimos sequi repudiandae minus ab deleniti totam officia id incidunt? Reply
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Delectus, suscipit exercitationem accusantium obcaecati quos voluptate nesciunt facilis itaque modi commodi dignissimos sequi repudiandae minus ab deleniti totam officia id incidunt? Reply